drugset / Trial / NCT06003621
Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients
Phase 2
Recruiting
96 enrolled
Omico
Hoffmann-La Roche · collabThe George Institute for Global Health, Australia · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II study will explore the effect of 2 monoclonal antibodies, tiragolumab and atezolizumab, in patients with locally advanced solid cancers which cannot be removed by surgery or have spread. Their cancers will have characteristics which may predict immune response to the study treatment. PD-L1 and TIGIT are immune receptors which can help cancers grow by evading the immune response and inhibiting the action of some immune cells. By blocking these receptors, tiragolumab and atezolizumab may work together to re-activate the body's anti-tumour immune response and kill cancer cells.
Timeline
- Start
- 2023-12-15
- Primary completion
- 2026-05-01
- Completion
- 2028-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Tiragolumab | Monoclonal antibody | 600 mg | Intravenous |